Hepatitis C virus (HCV) infection poses serious challenges to global health, affecting more than 170 million individuals. In high-income countries, more than twothirds of HCV infections are associated with injection drug use [1] . About 75% of individuals infected with HCV develop chronic HCV infection [2] and are at risk for long-term sequelae, including liver cirrhosis and hepatocellular carcinoma [3] . In former and active injecting drug users (DU), the prevalence of HCV ranges from 30 to 95% [4, 5] . In 2010, the modelled prevalence of chronic HCV infection in the (ever) injecting DU population (n = 4353) in Amsterdam was 80.7% [95% confidence interval (CI) 66.6-89.7] [6] .
Nowadays, treatment for HCV infection with pegylated interferon a (PEG-IFN) and ribavirin (RBV) is fairly adequate depending on the genotype, and more promising alternatives with direct acting antiviral agents for HCV are upcoming [7, 8] . Unfortunately, physicians seem to be reluctant to offer HCV treatment to DU because of their concerns about suboptimal patient adherence, potential psychiatric decompensation, the risk of premature mortality and the risk of reinfection after treatment [9] [10] [11] . We and others have shown that in a multidisciplinary programme, HCV treatment uptake and response in DU are comparable with a nondrug-using population [12] [13] [14] . Moreover, modelling studies have suggested that HCV treatment could contribute towards reducing the future HCV disease burden among DU [5, 15, 16] .
However, data on the risk of reinfection in DU after successful treatment are scarce. Apart from case reports, only four prospective studies among DU have been carried out. In a German study among 18 DU, zero to two cases of reinfection were observed, resulting in a reinfection rate of 0-4.1/100 person-years [17] . In the other three more recent, but relatively small studies (n = 9, 27 and 35), the overall reinfection rate varied from 0.6/100 person-years to 3.2 cases/100 person-years. However, when restricted only to those individuals returning to injection drug use, the reinfection rate was higher in these studies: 1.9 cases/100 person-years and 5.4 cases/100 person-years [18] [19] [20] .
To overcome potential barriers to the treatment of DU, more prospective data are required on the risk of reinfection after successful HCV treatment. The aim of this study was to evaluate the rate of HCV reinfection following the end of treatment (EOT) in a prospective cohort with DU who completed HCV therapy within a multidisciplinary programme. HCV strains were genotyped to discriminate between possible relapse, following HCV RNA-negativity at EOT, and true reinfection. In addition, we evaluated the mortality risk following EOT.
Materials and methods

Study population
The Amsterdam Cohort Studies (ACS) is an open and ongoing prospective cohort study among DU that was initiated in 1985 [21] . Participation is voluntary and informed consent is obtained at intake for every participant. The ACS was approved by the medical ethics committee of the Academic Medical Center. Within the ACS, the Drug Users Treatment for Chronic Hepatitis C (DUTCH-C) project was launched in December 2004 and has previously been reported in detail [12] . In brief, HCV treatment is provided to DU by ACS medical staff and a liver specialist from the Academic Medical Center (Amsterdam). Methadone and psychopharmaceutical medications are prescribed by addiction specialists and psychiatrists. Care providers from the methadone clinics provide support and observe the development of side-effects. No incentives were offered, and written informed consent was required for participation. To assess hepatitis B virus (HBV) status, all patients were routinely screened for anti-HBc, HBsAg and anti-HBs. HBV vaccination was offered for those uninfected with HBV. Patients received standardized HCV treatment with PEG-IFN along with RBV. Dosages were determined according to the standard of care and adjusted individually on the basis of side-effects. The treatment duration was 24 weeks (HCV genotypes 2 and 3) or 48 weeks (HCV genotypes 1 and 4).
Laboratory methods
Blood samples were tested qualitatively for HCV RNA using transcription-mediated amplification (Versant; Siemens Medical Solutions Diagnostics, Munich, Germany) with a lower detection limit of 5-10 IU/ml. Successful treatment, indicated by a sustained virologic response (SVR), was defined as having an undetectable HCV RNA level 24 weeks after treatment. When HCV RNA was detected at 24 weeks after treatment, plasma samples taken before and after treatment were compared by sequence analysis to distinguish between reinfection and relapse. After SVR, HCV RNA was tested at 6-12-monthly intervals.
Genotyping was performed using the primers and conditions as described previously by Murphy et al. [22] . Sequence alignments were created using Mega 5.0 (GenBank Accession No. JN426992-JN427013; The Biodesign Institute, Tempe, Arizona, USA) along with established reference sequences [23] to determine viral genotype. For phylogenetic analysis, the Tamura-3 parameter evolution model was chosen using the model test functionality in Mega 5.0 and the phylogenetic tree was constructed using the neighbourjoining method. The inferred phylogenies were tested with 1000 bootstrap replications [24] .
Causes of death
Patients were matched against the local and national registries to obtain information about their vital status. Cause of death (COD) was actively and systematically obtained, if available, from hospitals, general practitioners or coroners. Data were collected on the primary COD, contributing COD and underlying COD.
Statistical analyses
The incidence rate of reinfection was calculated using person-time techniques. The individual follow-up time was calculated from the EOT date until the last HCV RNAnegative test, date of HCV reinfection or death. The date of reinfection was determined as the midpoint between the last HCV RNA-negative and the first HCV RNA-positive visit. If spontaneous clearance of the reinfection was observed, patients were again considered at risk for another HCV reinfection from the first HCV RNA-negative visit following the previous reinfection (if confirmed by at least two HCV RNA-negative visits following the previous reinfection). Cumulative incidence curves were estimated for reinfection and death within a competing risks framework. The R language and environment for statistical computing, v2.8 [25] , and SPSS v19.0 (SPSS Inc., Chicago, Illinois, USA) were used for data analysis.
Results
General characteristics
Between April 2005 and November 2010, 69 patients were treated for HCV infection. SVR was achieved in 42 out of 69 patients (61%). Their characteristics at the start of treatment, during treatment and following EOT are presented in Table 1 . During follow-up, two patients with an SVR died. One patient died from pneumonia/sepsis; the other patient's death was classified as an undefined natural death at, respectively, 3.6 and 2.7 years after EOT. These two patients had their last HCV RNA-negative test 26 and 52 weeks before death and did not report any injection drug use during or after EOT.
One case became HCV RNA-positive and is described in more detail later.
Of the 27 out of 69 patients who did not achieve an SVR, 10 were defined as relapses after being HCV RNAnegative at EOT. All 10 patients were also studied for potential reinfection by phylogenetic analysis. In all cases, pretreatment and post-treatment sequences of genotypes 1a (n = 3) and 3a (n = 7) clustered closely together, which supports the notion of relapse.
Reinfection
One case of reinfection was observed; the case we present (study number 15895 in Fig. 1 ) involved a 56-year-old man of Dutch origin. He has had a history of ongoing injection drug use since 1974 and, in fact, injected shortly before the start of treatment. Before treatment, he was found to carry HCV genotype 1a at multiple visits. At the start of treatment, the baseline qualitative HCV RNA test was positive, HCV RNA by quantitative testing was less than 1000 IU/ml and ALT was 19 U/l. He was not infected with HIV and had previously achieved clearance of HBV infection. PEG-IFN and RBV therapy was initiated in March 2008. From week 2 onwards, qualitative HCV RNA-tests were undetectable until SVR. During treatment, he was on methadone maintenance therapy and continued injecting drug use. At 40 weeks following EOT (16 weeks after SVR), he reported a needlestick incident. The needle was from his female partner, who was HCV RNA-positive with genotype 1a and who had remained untreated. The qualitative HCV RNA-test was positive; however, the viral load level was less than 1000 IU/ml. Unfortunately, we could not characterize this reinfection because of the low viral load. Six weeks after the first positive test at reinfection, HCV RNA was undetectable by qualitative testing and remained undetectable (145 weeks after EOT and 107 weeks after reinfection).
The overall incidence of HCV reinfection was 0.76/100 person-years (95% CI 0.04-3.73). On restricting our analysis to those reporting injecting drug use, the incidence was 3.42/ 100 person-years (95% CI 0.17-16.90).
To examine the likelihood of mortality and reinfection following EOT, we constructed cumulative incidence curves, as shown in Fig. 2 . Reinfection occurred earlier in time following EOT than all-cause mortality. At 4 years after EOT, 2.4% (95% CI 0.0-6.9%) of DU were expected to have acquired an HCV reinfection and 8.6% (95% CI 0.0-19.8%) were expected to have died (all-cause mortality). Hence, 89.2% were expected to be alive and reinfection free at 4 years after EOT.
Discussion
The observed incidence rate of HCV reinfection was 0.76-3.42 cases/100 person-years. These results are comparable with the reinfection rates observed in other prospective studies performed in Germany, Norway, Canada and the USA [17] [18] [19] [20] . These studies did not include follow-up time after the clearance of a reinfection. In addition, the occurrence of possible reinfection in cases initially defined as relapses was not studied. If reinfections were present among the relapses, the reinfection rates in these studies might have been higher. Our observed reinfection rate is close to the average yearly incidence rate of primary HCV infection among ever-injecting DU in the ACS since 2005 (i.e. 0.35 cases/ 100 person-years). The HCV reinfection rate we found among injecting DU is considerably lower than the current incidence of HCV reinfection following the treatment of acute HCV infection in HIV-coinfected men who have sex with men (MSM) in Amsterdam (i.e. 15.2 cases/100 person-years) [26] .
We describe a case of spontaneous clearance of HCV reinfection following treatment and SVR for a chronic HCV infection. Grebely et al. [20] described the first case of spontaneous clearance after reinfection with HCV. Their patient had been treated for HCV genotype 3a and was reinfected with HCV genotype 1a, followed by spontaneous clearance [20] . Unfortunately, we could not genotype the reinfection of our case; however, as RNA became detectable again after SVR, this case is a reinfection by definition [27] . On the basis of the reported behaviour, the patient we described was probably reinfected with the HCV genotype 1a from his female partner. This observation of spontaneous clearance after reinfection of presumably genotype 1a following an SVR, when treated for a previous chronic infection with genotype 1a, may suggest that an enhanced immune response, as a result of therapy, allowed the patient to achieve clearance of the reinfection without treatment.
Following the spontaneous clearance of a primary HCV infection, strong and broad specific T-cell responses have been reported in the spontaneous clearance of HCV reinfection [28, 29] . However, our patient did not achieve spontaneous resolution of his primary HCV infection, which suggests that spontaneous clearance is multifactorial.
Follow-up time was calculated from EOT instead of the date of SVR; therefore, our follow-up time increased with 24 weeks per individual. However, two recent studies have shown that HCV reinfections can occur in the window phase between EOT and SVR in HCV-HIV-coinfected MSM treated for acute HCV [30] . Importantly, these studies showed that patients originally diagnosed as late relapses should be re-evaluated for reinfections. The distinction between relapse and reinfection has important clinical consequences and should therefore be considered prospectively by clinicians. The definition of relapse or reinfection in the first 6 months after EOT should, in a population with ongoing HCV risk behaviour (e.g. injecting drug use), always be based on phylogenetic analysis. In this study, we used part of the NS5B gene for this analysis, because the phylogenetic signal in this population was sufficient to distinguish between relapse and reinfection, as pretreatment sequences were unique for each patient. In populations where highly similar viruses are circulating, for example the recent epidemic of acute HCV in HIVcoinfected MSM, the genomic region analysed in the study may not be appropriate. Formally, we cannot completely rule out that the relapse patients with clustering of pretreatment and post-treatment samples were reinfected by the same source. However, given the minor genetic Phylogenetic tree of HCV NS5B sequences of one reinfection case and relapses (n = 10) of DU treated for HCV in Amsterdam. One reinfection (15895, ') was determined by TMA but could not be genotyped. This case reported a needlestick incident from his HCV-positive partner (15895 partner, '). Among relapses (n = 10), samples taken before (pre) and after (post) treatment clustered closely together, supporting the notion of relapse rather than reinfection. DU, drug users; HCV, hepatitis C virus; TMA, transcription-mediated amplification.
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distances between pretreatment and post-treatment samples and the high evolutionary rate of HCV, this seems highly unlikely.
One of the limitations of this study is that spontaneously resolved reinfections may have been missed because of 6-12-monthly testing for HCV RNA. This would lead to an underestimation of the observed HCV reinfection rate, but reinfections resulting in chronic infection would have been noticed. The results from this study are based on treatment in DU in a multidisciplinary setting with access to low-threshold comprehensive harm reduction programmes and might not be applicable for treatment in a different setting. Another limitation is that variables on drug use behaviours were self-reported and may be subjective according to socially desirable responses.
Conclusion
We found a low reinfection rate after the successful treatment of HCV infection in active DU participating in a multidisciplinary HCV treatment programme in a city with comprehensive harm reduction programmes for DU. Active drug use, including injecting, during and after treatment, was relatively common; however, it should not preclude access to treatment for HCV. Cumulative incidence for HCV reinfection and survival among DU at risk for reinfection (n = 42) since the end of successful HCV treatment, within a competing risk framework. DU, drug users; HCV, hepatitis C virus.
